U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H32ClN5O2.ClH
Molecular Weight 494.457
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPATASERTIB MONOHYDROCHLORIDE

SMILES

Cl.CC(C)NC[C@@H](C(=O)N1CCN(CC1)C2=C3[C@H](C)C[C@@H](O)C3=NC=N2)C4=CC=C(Cl)C=C4

InChI

InChIKey=DGGYVQQEWGRNDH-GJYOXNSLSA-N
InChI=1S/C24H32ClN5O2.ClH/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23;/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3;1H/t16-,19-,20-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C24H32ClN5O2
Molecular Weight 457.996
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.biooncology.com/pipeline-molecules/ipatasertib.html | https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=669600 | http://meetinglibrary.asco.org/content/152669-156

Ipatasertib, an investigational Akt inhibitor, is currently in clinical development based on its potential to specifically target Akt in tumors with activated Akt signaling. Preclinical data have shown that ipatasertib selectively decreased cell viability and increased apoptosis in tumor cell lines characterized by activated Akt. Ipatasertib is advancing in clinical development including three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer. The most commonly reported adverse events associated with Ipatasertib were Grade 1-2 diarrhea, nausea, fatigue, vomiting, decreased appetite and rash.

Approval Year

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
2012 Sep 27
Patents

Sample Use Guides

600 mg once daily on days 1 to 7 of each 14-day cycle
Route of Administration: Oral
Ipatasertib has a potent antiproliferative effect on LNCaP cells with an IC50 of 95 ± 16 nM. In PC3, MCF7-neo/HER2, and BT474M1 cell lines, Ipatasertib was able to inhibit overall viability with IC50 values in the range of 1−4 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:22:40 GMT 2023
Edited
by admin
on Sat Dec 16 18:22:40 GMT 2023
Record UNII
M94BW9PF2L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IPATASERTIB MONOHYDROCHLORIDE
Common Name English
IPATASERTIB HYDROCHLORIDE [JAN]
Common Name English
IPATASERTIB HYDROCHLORIDE
Common Name English
1-PROPANONE, 2-(4-CHLOROPHENYL)-1-(4-((5R,7R)-6,7-DIHYDRO-7-HYDROXY-5-METHYL-5H-CYCLOPENTAPYRIMIDIN-4-YL)-1-PIPERAZINYL)-3-((1-METHYLETHYL)AMINO)-, HYDROCHLORIDE (1:1), (2S)-
Common Name English
(2S)-2-(4-CHLOROPHENYL)-1-(4-((5R,7R)-6,7-DIHYDRO-7-HYDROXY-5-METHYL-5H-CYCLOPENTAPYRIMIDIN-4-YL)-1-PIPERAZINYL)-3-((1-METHYLETHYL)AMINO)-1-PROPANONE HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
72188570
Created by admin on Sat Dec 16 18:22:40 GMT 2023 , Edited by admin on Sat Dec 16 18:22:40 GMT 2023
PRIMARY
FDA UNII
M94BW9PF2L
Created by admin on Sat Dec 16 18:22:40 GMT 2023 , Edited by admin on Sat Dec 16 18:22:40 GMT 2023
PRIMARY
CAS
1489263-16-2
Created by admin on Sat Dec 16 18:22:40 GMT 2023 , Edited by admin on Sat Dec 16 18:22:40 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE